Author/Editor		Ocvirk, Janja
Title		Naše izkušnje zdravljenja z rituximabom (MabThero) pri bolnikih s folikularnim limfomom
Translated title		Our experiences in rituximab therapy of patients with follicular lymphoma
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 39, št. Suppl 5
Publication year		2000
Volume		str. 123-8
Language		slo
Abstract		Rituximab is a monoclonal antibody that reacts against CD 20 expressed on 90% of B cell non-Hodgkin's lymphomas. The monoclonal antibody mediates complement and antibody dependent cell-mediated cytotoxicity and has a direct antiproliferative effect against malignant B cell lines in vitro. Rituximab induced objective responses in 50% patients with low grade or follicular B-cell lymphomas (relapsed or chemoresistant). We represent 5 patients with relapsed or chemoresistant follicular lymphoma; who received an outpatient treatment course of 375 mg/m2 rituximab dose applaied intravenously weekly in four doses. Rituximab therapy has significant anti-lymphoma activity without toxic effects commonly observed in standard combinations of chemotherapevtic regimens. It offers a safe, non-myelosupressive well-tolerated therapy in patients with relapsed or chemoresistant follicular lymphoma.
Summary		Rituximab je himerno protitelo proti antigenu CD 20, specifično za celice B. CD 20 izraža oko- li 90% B celičnih ne-Hodgkinovih limfomov. Rituximab z vezavo komplementa in protiteles povzroči lizo celic. Na B-celične linije deluje tudi direktno antiproliferativno. Bolniki s ponovitvijo in odpornostjo folikularnega limfoma v 50% odgovorijo na zdravljenje z rituximabom. Predstavljamo pet bolnikov s ponovitvijo in/ali odpornostjo folikularnega limfoma, ki smo jih ambulantno zdravili z rituximabom 375 mg/m2; zdravili smo intravenozno, zdravilo apli- cirali enkrat tedensko, v štirih odmerkih. Zdravljenje z rituximabom je visoko specifično za bolnike z B-celičnim limfomom, brez toksičnosti, ki so običajne za kombinirane kemoterapije. Nudi varno, nemielosupresivno zdravljenje, ki ga bolniki s ponovitvijo ali odpornostjo folikularnega limfoma dobro prenašajo.
Descriptors		LYMPHOMA, FOLLICULAR ANTIGENS, CD20 ANTIBODIES, MONOCLONAL TREATMENT OUTCOME